The World Health Organization (WHO) has recommended Regeneron Pharmaceutical’s antibody cocktail therapy, casirivimab and imdevimab, to treat non-severe Covid-19 patients who are at high risk of hospitalisation. The agency also called for a lower price and equitable distribution of the treatment, which is currently being manufactured by Roche. WHO also asked Regeneron to address the high price and limited availability of the treatment, calling for the sharing of technology to facilitate the production of biosimilar versions.
Moderna has entered an agreement with the Government of Peru to supply 20 million doses of its Covid-19 vaccine, beginning in the first quarter of next year. The jab is not currently approved in Peru, but the company intends to work with regulators in the country to obtain required approvals before distributing the vaccine.
Kintor Pharmaceutical has secured approval from the Brazilian Health Regulatory Agency, ANVISA, to conduct a Phase III clinical trial of proxalutamide for the treatment of patients hospitalised with Covid-19. The multi-regional trial is set to recruit 1,030 patients to assess the safety and efficacy of the drug. Data from the trial is expected to support the Emergency Use Authorisation of proxalutamide and the subsequent commercialisation in Brazil.